Cambridge Investment Research Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62K	Hold	15,554	–	–	﹤0.01%	3839
2025 Q4	$109K	Sell	15,554 -3,900	-20%	-$21.8K	﹤0.01%	3692
2025 Q3	$90K	Hold	19,454	–	–	﹤0.01%	3601
2025 Q2	$106K	Buy	19,454 +3,900	+25%	+$20.9K	﹤0.01%	3464
2025 Q1	$86K	Hold	15,554	–	–	﹤0.01%	3369
2024 Q4	$78K	Hold	15,554	–	–	﹤0.01%	3346
2024 Q3	$72K	Hold	15,554	–	–	﹤0.01%	3303
2024 Q2	$86K	Hold	15,554	–	–	﹤0.01%	3174
2024 Q1	$152K	Hold	15,554	–	–	﹤0.01%	3090
2023 Q4	$131K	Buy	+15,554	New	+$80.1K	﹤0.01%	2997

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Cambridge Investment Research Advisors's TLSI Position: Q1 2026 in Review

Cambridge Investment Research Advisors held its TriSalus Life Sciences (TLSI) position steady in Q1 2026 at 15,554 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

Cambridge Investment Research Advisors first reported a position in TLSI in Q4 2023 and has held it in 10 quarters since. The position peaked at $152K in Q1 2024. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

Cambridge Investment Research Advisors held 15,554 shares of TriSalus Life Sciences worth $62K as of Q1 2026.
Cambridge Investment Research Advisors left its TriSalus Life Sciences share count unchanged in Q1 2026.
TriSalus Life Sciences made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3839 holding.
Cambridge Investment Research Advisors first reported a position in TriSalus Life Sciences in Q4 2023 and has held it in 10 quarters since.
Cambridge Investment Research Advisors's TriSalus Life Sciences position peaked at $152K in Q1 2024.
84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.